Request Demo

Last update 31 Dec 2024

Oxycodone

Last update 31 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryOxycodone, a potent opioid analgesic, also referred to as a narcotic, is a medication used in the management of pain. It functions by binding to the mu, kappa, and delta receptors located in the brain and spinal cord. The elaborate chemical name of oxycodone is 4,5 α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one. Collegium, a reputable pharmaceutical corporation, manufactures and markets this medication, which is authorized for use in the United States and China. Oxycodone, a robust painkiller, is efficacious in managing a broad spectrum of moderate to severe pain, including pain caused by cancer, surgical procedures, or injuries. Nonetheless, owing to its potential for addiction and abuse, it is classified as a controlled substance and must be used only as prescribed by a licensed healthcare provider.

Drug Type

Small molecule drug

Synonyms

(-)-14-Hydroxydihydrocodeinone, 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one

+ [21]

Target

Opioid receptors

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

PainPain, PostoperativeAcute Pain+ [1]

Inactive Indication

Cancer PainChronic PainLow Back Pain+ [3]

Originator Organization

Collegium Pharmaceutical, Inc.

Active Organization

Ensysce Biosciences, Inc.Napp Pharmaceutical Holdings Ltd.

Collegium Pharmaceutical, Inc.

Inactive Organization

Mundipharma Research GmbH & Co. KG

Beijing Mengdi Pharmaceutical Co. Ltd.Grunenthal SA

Drug Highest PhaseApproved

First Approval Date

CN (21 Jan 2004),

Pain

RegulationBreakthrough Therapy (US), Fast Track (US)

Structure/Sequence

Molecular FormulaC18H21NO4

InChIKeyBRUQQQPBMZOVGD-XFKAJCMBSA-N

CAS Registry76-42-6

437

Clinical Trials associated with Oxycodone

NCT06602271

/ Not yet recruitingPhase 3

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain After Abdominoplasty

The goal of this clinical trial is to evaluate the analgesic activity of PF614 (an oral oxycodone prodrug extended-release analgesic) for control of postsurgical pain in subjects scheduled for abdominoplasty surgery. The main question to be answered is:
• To assess the analgesic efficacy of PF614 compared to oxycodone hydrochloride (an immediate-release opioid analgesic) and placebo in subjects with moderate to severe pain following abdominoplasty Participants will be asked to take oral blinded doses of study medication at about one hour before surgery starts, and then every 6 hours after surgery for up to 4 days.
Participants will be asked to:
* Rate their pain on a 0-10 numerical rating scale (NRS) at various timepoints up to 5 days following surgery;
* Tell us about the need for rescue medication if they continue to have moderate-to-severe pain;
* Tell us about any side effects or adverse effects that they may experience to help us understand the safety and tolerability of the test medications;
* Provide periodic blood samples to help us understand how much study drug is in their system.
Participants will stay in a clinic setting and be monitored for safety for 5 days following surgery. We anticipate that participants will be discharged on Day 5, pending medical review, and then keep a diary to record study-related pain and adverse effects for an additional 2-4 days after discharge.

Start Date01 Mar 2025

Sponsor / Collaborator

Ensysce Biosciences, Inc.

NCT06721988

/ Not yet recruitingNot ApplicableIIT

Exploring the Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Pain in Adult Patients Underwent Laparoscopic-assisted Abdominal Major Surgery

The goal of this clinical trial is to learn if the administration of oxycodone for preventive analgesia works to reduce the chronification of acute postoperative pain in adult participants undergoing major abdominal surgery. The main question it aims to answer is:
• Does administration of oxycodone before surgical incision reduce the occurrence of chronic pain or relieve the chronic pain symptoms 3 months after the operation? Researchers will compare oxycodone + parecoxib sodium to placebo + parecoxib sodium combinations to see if oxycodone works to reduce the chronification of acute postoperative pain.
Participants will:
* Take oxycodone + parecoxib sodium or placebo + parecoxib sodium combinations before the surgical incision
* Cooperate with the follow-up staffs and complete some checkups or tests within 3 months after the operation.

Start Date01 Jan 2025

Sponsor / Collaborator

Tongji Hospital Tongji Medical College of HUST

[+2]

NCT06539741

/ Not yet recruitingNot ApplicableIIT

Mechanisms of Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction

Nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, are recommended as first-line treatment for post-surgical dental pain. However, there is variability in analgesic response, and some patients require supplemental opioids for adequate pain relief. The goal of this study is to identify the factors that contribute to the need for opioid after third molar extraction to help limit unnecessary opioid prescriptions in patients who will have good pain relief with ibuprofen alone.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Pennsylvania

[+1]

100 Clinical Results associated with Oxycodone

100 Translational Medicine associated with Oxycodone

100 Patents (Medical) associated with Oxycodone

4,897

Literatures (Medical) associated with Oxycodone

01 Mar 2025·NEUROPHARMACOLOGY

Paternal morphine alters offspring circulating beta-endorphin and corticosterone responses to oxycodone and cocaine

Article

Author: Isgate, Sara B ; Byrnes, Elizabeth M ; Budge, Kerri E ; Vassoler, Fair M

BACKGROUND:

The opioid epidemic is leading to increased opioid use in adolescent populations. A growing body of evidence suggests that taking opioids during adolescence can disrupt normal development and impact future offspring. This study investigates the impact of paternal morphine exposure during adolescence on the hypothalamic-pituitary-adrenal (HPA) axis and release of endorphins in the offspring.

METHODS:

Male rats were administered morphine once a day from postnatal day (PND)30-39 using an increasing dosing regimen (5-25mg/kg/day increasing every other day). They were mated during adulthood to drug naïve females. Their offspring were assessed for circulating beta-endorphin (βE) and corticosterone levels on PND30 (a timepoint prior to puberty in both sexes) in response to an acute injection of saline, oxycodone (1 mg/kg, i.p.) or cocaine (10 mg/kg, i.p.). At PND60, naïve littermates were catheterized so that a within-subjects design could be implemented to measure βE and corticosterone in response to saline, oxycodone, or cocaine.

RESULTS:

In males, βE levels in the plasma were increased in Mor-F1 males compared to Sal-F1 males regardless of the acute injection. This elevation was observed at PND30 and PND60. There were no differences in female circulating βE. In terms of corticosterone, male Mor-F1 offspring had blunted corticosterone at PND30, but elevated corticosterone in response to oxycodone at PND60. The females also tended towards lower corticosterone prior to puberty but had significantly elevated levels of circulating corticosterone following an acute cocaine injection.

CONCLUSION:

Paternal morphine exposure during adolescence induces sex- and drug-specific changes in secreted hormone responses in offspring. The alterations in βE and corticosterone levels suggest mechanisms through which adolescent opioid exposure can impact endocrine functions of future offspring. These findings contribute to the understanding of intergenerational transmission of substance use effects.

01 Feb 2025·BIOMATERIALS

The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines

Article

Author: Pravetoni, Marco ; Hamid, Fatima A ; Rostamizadeh, Kobra ; Walter, Debra L. ; Runyon, Scott ; Vigliaturo, Jennifer R ; Zhang, Chenming ; Vigliaturo, Jennifer R. ; DeHority, Riley ; Hamid, Fatima A. ; Bian, Yuanzhi ; Hu, He ; Ehrich, Marion ; Walter, Debra L

The current opioid epidemic is one of the most profound public health crises facing the United States. Despite that it has been under the spotlight for years, available treatments for opioid use disorder (OUD) and overdose are limited to opioid receptor ligands such as the agonist methadone and the overdose reversing drugs such as naloxone. Vaccines are emerging as an alternative strategy to combat OUD and prevent relapse and overdose. Most vaccine candidates consist of a conjugate structure containing the target opioid attached to an immunogenic carrier protein. However, conjugate vaccines have demonstrated some intrinsic shortfalls, such as fast degradation and poor recognition by immune cells. To overcome these challenges, we proposed a lipid-PLGA hybrid nanoparticle (hNP)-based vaccine against oxycodone (OXY), which is one of the most frequently misused opioid analgesics. The hNP-based OXY vaccine exhibited superior immunogenicity and pharmacokinetic efficacy in comparison to its conjugate vaccine counterpart. Specifically, the hNP-based OXY vaccine formulated with subunit keyhole limpet hemocyanin (sKLH) as the carrier protein and aluminum hydroxide (Alum) as the adjuvant (OXY-sKLH-hNP(Alum)) elicited the most potent OXY-specific antibody response in mice. The induced antibodies efficiently bound with OXY molecules in blood and suppressed their entry into the brain. In a following dose-response study, OXY-sKLH-hNP(Alum) equivalent to 60 μg of sKLH was determined to be the most promising OXY vaccine candidate moving forward. This study provides evidence that hybrid nanoparticle-based vaccines may be superior vaccine candidates than conjugate vaccines and will be beneficial in treating those suffering from OUD.

01 Feb 2025·BIOCHEMICAL PHARMACOLOGY

Positive allosteric modulation of µ-opioid receptor – A new possible approach in the pain management?

Review

Author: Król, Wojciech ; Machelak, Weronika ; Zielińska, Marta

The antinociceptive effect of the opioid drugs is achieved through activation of the µ-opioid receptor (MOP). The orthosteric and allosteric sites of opioid receptors may be modulated, orthosteric site by endogenous i.e.β-endorphin and exogenous opioids (morphine, oxycodone, fentanyl); whereas BMS-986121, BMS-986122, Comp5, MS1, Ignavine or even oxytocin act on the allosteric site of the MOP. Opioid therapy is associated with numerous side effects, such as: respiratory depression, sedation, constipation, and importantly, prolonged therapy can influence the development of tolerance, overdose, and addiction. Opioid tolerance is a result of MOP internalization and desensitization, preceded by MOP phosphorylation, performed by protein kinases such as: PKA, PKC, GRKs or CaMKII. In vitro and in vivo data suggest that positive allosteric modulators may enhance antinociception triggered by orthosteric ligands and reduce side effects, which would allow the dose of opioids to be reduced and thus provide a more effective therapy. In this review, we present that positive modulation of the allosteric sites of MOP may constitute a new strategy for pain therapy.

169

News (Medical) associated with Oxycodone

19 Dec 2024

·www.drugs.com

U.S. Life Spans Rebound from Pandemic Lows, Helped by Drop in Fatal Overdoses

THURSDAY, Dec. 19, 2024 -- After years of decline, U.S. life expectancy is finally on the rise again for the first time since 2019, new government research shows. This turnaround was driven in part by a decline in drug overdose deaths, which had risen dramatically as a result of the opioid epidemic, according to a second report from the U.S. Centers for Disease Control and Prevention. That includes the first reduction in OD deaths caused by powerful synthetic opioids like fentanyl and tramadol, researchers said. “The age-adjusted rate for drug overdose deaths involving synthetic opioids other than methadone decreased from 2022 to 2023, the first such decrease since the large increases that began in 2013,” concluded the research team led by Matthew Garnett , an injury epidemiologist and statistician with the CDC’s National Center for Health Statistics (NCHS). “The rate also decreased for deaths involving natural and semisynthetic opioids and heroin between 2022 and 2023,” the team added. Life expectancy at birth in 2023 was 78.4 years for the total population, an increase of 0.9 years from 77.5 in 2022, CDC researchers reported. For men, life expectancy increased 1 year, from 74.8 in 2022 to 75.8 in 2023. Meanwhile, women saw a 0.9-year increase, from 80.2 in 2022 to 81.1 in 2023. “From 2022 to 2023, age-adjusted death rates decreased for 9 of the 10 leading causes of death,” wrote the life expectancy research team led by Elizabeth Arias , a health scientist with the NCHS. Deaths due to heart disease, accidental injury, stroke, respiratory disease, Alzheimer’s disease, diabetes, kidney disease, liver disease and COVID-19 all fell significantly between 2022 and 2023, researchers found. The rate of cancer deaths also went down, but not significantly, the report says. The end of the pandemic likely contributed to the increase in life expectancy, researchers said. “The most notable change was for COVID-19, which dropped from the 4th leading cause in 2022 to the 10th leading cause in 2023,” the researchers wrote. Overall, COVID deaths decreased more than 73% between 2022 and 2023, falling from 44.5 deaths to 11.9 deaths per 100,000, researchers said. A decrease in drug OD deaths also contributed to improved life expectancy. The rate of drug overdose deaths fell from 32.6 per 100,000 in 2022 to 31.3 per 100,000 in 2023, researchers said. Drug OD deaths are considered accidental injury deaths. These results jibe with statistics released last week by the CDC, which reported that drug OD deaths had decreased 17% between July 2023 and July 2024. However, the OD death rate is still 3.5 times what it was in 2003, when 8.9 people for every 100,000 died by drug overdose. Drug OD deaths related to synthetic opioids declined by 2.2% between 2022 and 2023, results show -- the first significant decline in OD deaths related to synthetic opioids like fentanyl since 2003, researchers added. Drug overdose deaths related to natural opioids like morphine, oxycodone and hydrocodone also declined 17.1%, between 2022 and 2023, and OD deaths caused by heroin decreased 33.3%. However, OD death rates for cocaine increased by 4.9% between 2022 and 2023, and OD deaths from stimulants like methamphetamine increased by 1.9%, researchers said. Lastly, infants did not seem to benefit from the declining death rates, researchers found. “The infant mortality rate of 560.2 infant deaths per 100,000 live births in 2023 was not significantly different from the rate in 2022,” the researchers wrote. The ten leading causes of infant death in 2023 -- birth defects, low birth weight, sudden infant death syndrome, unintentional injuries, maternal complications, bacterial sepsis of newborn, cord and placental complications, respiratory distress of newborn, intrauterine hypoxia and birth asphyxia, and diseases of the circulatory system -- accounted for more than 65% of all infant deaths, researchers concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

10 Dec 2024

·www.accesswire.com

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt of commitment of future supply of GMP nafamostat, a critical component of PF614-MPAR. This agreement fully secures the supply chain and allows Ensysce to reference the nafamostat Drug Master File of Aurore Life Sciences, a renowned specialty drug manufacturer.Dr. Lynn Kirkpatrick commented, "We are pleased to have received this early interest and commitment from Aurore as nafamostat is a vital component of our overdose protection program PF614-MPAR. Having a secure supply of this drug substance will accelerate our finalizing the drug product for PF614-MPAR, which is rapidly moving through clinical development. Ensysce has initiated additional programs with nafamostat as a single agent for other indications which will also benefit from this commitment, so we welcome Aurore as a critical partner in our pipeline development."About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage pharmaceutical company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.About Aurore Life SciencesAurore Life Sciences, established in 2017, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, offering high-quality, affordable bulk drug solutions to over 55 countries worldwide. With a pure-play focus on APIs and intermediates, Aurore is a fully backward-integrated pharmaceutical company dedicated to delivering to all regulated markets globally.Forward-Looking StatementsStatements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.Ensysce Biosciences Company ContactLynn Kirkpatrick, Ph.D.Chief Executive Officer(858) 263-4196Ensysce Biosciences Investor Relations Contact:MZ Group North America Shannon Devine203-741-8811[email protected]SOURCE: Ensysce Biosciences Inc.

04 Dec 2024

·www.accesswire.com

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~ SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the initiation of a strategic partnership with a leading specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR drug products.This collaboration underscores a shared commitment to achieving swift regulatory approval and efficient development of the Company's innovative drug products. The strategic partnership will provide Ensysce with the clinical trial material, drug products for regulatory submissions, and initial commercial batches of PF614 and PF614-MPAR. The partner's services will also encompass the complete manufacturing process, including packaging, labeling, and shipment of the products, ensuring a seamless transition from regulatory approval to market entry.As part of this partnership, the specialty drug manufacturer will take an equity position in Ensysce, facilitating resource allocation to clinical trials and commercialization activities. The agreement also secures key Chemistry Manufacturing and Control (CMC) elements of the New Drug Application (NDA) submission.Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences, stated, "This partnership strengthens our ability to deliver quality drug products for clinical and commercial purposes starting with PF614 and PF614-MPAR. It ensures that all aspects of manufacturing, packaging, and distribution are handled efficiently, enabling us to focus on helping patients suffering from severe pain with innovative and safer solutions."About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage pharmaceutical company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP TM ) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.Forward-Looking StatementsStatements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.Ensysce Biosciences Company ContactLynn Kirkpatrick, Ph.D.Chief Executive Officer(858) 263-4196Ensysce Biosciences Investor Relations Contact:MZ Group North America Shannon Devine203-741-8811[email protected]SOURCE: Ensysce Biosciences Inc.

NDA

100 Deals associated with Oxycodone

External Link

KEGG	Wiki	ATC	Drug Bank
D05312	Oxycodone	N02AA05	DB00497

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	CN	Napp Pharmaceutical Holdings Ltd.	21 Jan 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tumor pain	Phase 3	DE	Mundipharma Research GmbH & Co. KG	01 Nov 2014
Low Back Pain	Phase 3	US	Collegium Pharmaceutical, Inc.	01 Aug 2012
Pain, Postoperative	Phase 3	-	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Jul 2011
Cancer Pain	Phase 3	-	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Jan 2011
Neoplasms	Phase 3	-	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Jan 2011
Osteoarthritis	Phase 3	BE	Mundipharma Research GmbH & Co. KG	01 May 2009
Osteoarthritis	Phase 3	CZ	Mundipharma Research GmbH & Co. KG	01 May 2009
Osteoarthritis	Phase 3	FI	Mundipharma Research GmbH & Co. KG	01 May 2009
Osteoarthritis	Phase 3	DE	Mundipharma Research GmbH & Co. KG	01 May 2009
Osteoarthritis	Phase 3	HU	Mundipharma Research GmbH & Co. KG	01 May 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	zpawtytyou(firavvgvdh) = vodvxuqjcf tghknupsxb (nhdtobjtuj, xcduueeiee - afkilsqina) View more	-	19 Sep 2024
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	zpawtytyou(firavvgvdh) = aytjzrripv tghknupsxb (nhdtobjtuj, pcqsbdmkha - hrpoatoefj) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone (Opioid Pain Control)	hlnyfvuiui(zqkjpxwpvo) = xtaufwtbwm qllnnvismr (qttpsumydw, aououpljal - sisqbfznfn) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	hlnyfvuiui(zqkjpxwpvo) = azysbsyznw qllnnvismr (qttpsumydw, rrpytovpzt - oppwfybykk) View more
NCT04015908 (CTgov)	Phase 4	-	100	Pregabalin+Acetaminophen+Celecoxib+Oxycodone (Multi-modal)	togkfqjuhk(smispbdpnj) = xczglfbrdv wzoqpeqmiq (uvnmfcgffc, gixaiknoha - dtmqdkoerf) View more	-	08 Jul 2024
				Percocet (Control)	togkfqjuhk(smispbdpnj) = cixlvfadly wzoqpeqmiq (uvnmfcgffc, jaslqbglve - tjhhmslsgg) View more
NCT04296396 (Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Pubmed \| Obstet Gynecol)	Phase 3	-	-	Opioid (IOPP with shared decision making)	tzuxhgiryn(oyvxfatdbw) = vvjcyujqee csvkjhobmz (csygmbzfas ) View more	Positive	10 Jun 2024
				Fixed quantity (20 tablets of 5 mg oxycodone)	tzuxhgiryn(oyvxfatdbw) = ycnfbduqmz csvkjhobmz (csygmbzfas ) View more
PF614-201 (Biospace) Manual	Phase 2	-	-	PF614	nlbdhqdwbl(xcwcythklf) = demonstrated time-to-efficacy onset for the analgesia effect and significant decrease of pain intensity versus placebo of PF614 at two different dose levels jsmlhkzjtx (ybkzfthath )	Positive	14 Dec 2023
				placebo
WSC2023	Not Applicable	-	-	Opioid medications	qxiradagit(viawhkcthg) = syqmcvcmey mxbqrphpxd (wkhfjdwweb )	-	23 Oct 2023
NCT04285853 (CTgov)	Phase 4	Anterior Cruciate Ligament Injuries	98	Oxycodone (Oxycodone Arm)	aqutxrxzpb(xsmhmiejdj) = owztryexjr hrinxfsigz (jxibddromr, bsjbatwyqo - ojailtcnqy) View more	-	11 Oct 2023
				Placebo oral tablet (Placebo Arm)	aqutxrxzpb(xsmhmiejdj) = eqzhymdeyh hrinxfsigz (jxibddromr, ysimymnfpx - xkafoxtyku) View more
NCT04149964 (CTgov)	Phase 4	Fistula \| Pain, Postoperative	65	Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet+Acetaminophen 325 mg Oral Tablet (Standard of Care Arm)	tizrpledgc(omwgecpdvm) = jzfryirlso qobtcdbxrv (psfzpbtful, glcwzbnynt - smrqrefikh) View more	-	31 Aug 2023
				Acetaminophen 650 mg Oral Tablet+OxyCODONE 5 mg Oral Tablet (Study Arm)	tizrpledgc(omwgecpdvm) = lhdjketopf qobtcdbxrv (psfzpbtful, pqwypohurn - xeolbjqqpv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis